SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ACMI - Accumed Inc. -- Ignore unavailable to you. Want to Upgrade?

To: CARYTRE who wrote (1298)1/28/1998 8:53:00 PM
From: joemjo  Respond to of 1894
 
C.S.

Either that or we all added today<g> Of course we are the pros so I guess that is a redundancy.

Todd



To: CARYTRE who wrote (1298)1/29/1998 12:34:00 PM
From: george  Respond to of 1894
 
Cary,
At first blush, the news means that Neopath's primary screening will take over the screening......however, at a second look, you realize that 75% of slides need to be screened by a cytologist, and it doesn't make sense to me to buy an automatic tester unless you are a big volume lab...and even then I would think that a false negative with no human screening would cream a lab in a law suit....
George


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News